Scholarlink

<p>Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月18日

查看全文
  • Benjamin W. Muir,
  • Jennifer A. E. Payne,
  • Jennifer H. Martin,
  • Riley O’ Shea,
  • Sarigama Rajesh,
  • Lewis D. Blackman,
  • Hsin-Hui Shen,
  • Chad Heazlewood,
  • Vipul Bansal,
  • Branwen Morgan

摘要

Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.